In vitro antimicrobial susceptibility of periodontopathic Actinobacillus actinomycetemcomitans to roxithromycin and erythromycin

Oral Microbiology and Immunology

Volumn 12, Issue 6, 1997, Pages 366-371

  Piccolomini, R ^a   Di Bonaventura, G ^a   Catamo, G ^a   Picciani, C ^a   Paolantonio, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Actinobacillus actinomycetemcomitans; Erythromycin; Microbial sensitivity tests; Roxithromycin

Indexed keywords

EID: 0031543517     PISSN: 09020055     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-302x.1997.tb00740.x     Document Type: Article

References (48)

1. Acar JF, Goldstein FW. In vitro activity against gram-positive and gram-negative bacteria. In: Neu HC, Young LS, Zinner SH, ed. The new macrolides, azalides and streptogramins. Pharmacology and clinical applications. New York: Marcel Dekker, 1993: 13-24.
2. Ainamo J, Bay I. Problems and proposals for recording of supragingival plaque and gingivitis. Int Dent J 1975: 25: 229-235.
3. Amano K, Nishihara T, Shibuya N, Noguchi T, Koga T. Immunochemical and structural characterization of a serotype-specific polysaccharide antigen from Actinobacillus actinomycetemcomitans Y4 (serotype b). Infect Immun 1989: 57: 2942-2946.
4. Asikainen S, Lai C-H, Alaluusua S, Slots J. Distribution of Actinobacillus actinomycetemcomitans serotypes in periodontal health and disease. Oral Microbioi Immunol 1991: 6: 115-118
5. Asikainen S, Jousimies-Somer H, Kanervo A, Saxén L. The immediate efficacy of adjunctive doxycycline in treatment of localized juvenile periodontitis. Arch Oral Biol 1990: 35: 231S-234S.
6. Baker PJ, Evans RT, Slots J, Genco RJ. Antibiotic susceptibility of anaerobic bacteria from the human oral cavity. J Dent Res 1985: 64: 1233-1244.
7. Bartlett RC. Medical microbiology: quality cost and clinical relevance. New York: John Wiley & Sons, 1974: 9-13.
8. Bragd L, Dahlén G, Wikström M, Slots J. The capability of Actinobacillus actinomycetemcomitans, Bacteroides gingivalis, and Bacteroides intermedius to indicate progressive periodontitis; a retrospective study. J Clin Periodontol 1987: 14: 95-99.
9. Christensson LA, Slots J, Zambon JJ, Genco RJ. Transmission and colonization of Actinobacillus actinomycetemcomitans in localized juvenile periodontitis patients. J Periodontol 1985: 56: 127-131.
10. Gmür R, McNabb H, van Steenbergen TJM et al. Sero-classification of hitherto nontypable Actinobacillus actinomycetemcomitans strains: evidence for a new serotype e. Oral Microbiol Immunol 1993: 8: 116-120.
11. Goldstein EJC, Citron DM, Vagvolgyi AE, Finegold SM. Susceptibility of bite wound bacteria to seven oral antimicrobial agents, including RU-985, a new erythromycin considerations in choosing empiric therapy Antimicrob Agents Chemother 1986: 29: 556-559.
12. Hamada S, Fujiwara T, Shimauchi H et al. Antimicriobial activities of thiolactomycin against gram-negative anaerobes associated with periodontal disease. Oral Microbiol Immunol 1990: 5: 340-345.
13. Jehl J, Kolbe R, Scheimberg A, Rosembaum M, Monteil H. Penetration of roxithromycin into gingival tissue. Diagn Microbiol Infect Dis 1992: 15: 77S-79S.
14. Jorgensen JH, Howell AW, Maher LA. Antimicrobial susceptibility testing of less commonly isolated Haemophilus species using Haemophilus test medium. J Clin Microbiol 1990: 28: 985-988.
15. Jousimies-Somer H, Asikainen S, Soumala P, Summanen P. Activity of metronidazole and its hydroxy metabolite against clinical isolates of Actinobacillus actinomycetemcomitans. Oral Microbiol Immunol 1988: 3: 32-34.
16. Kilian M, Frederiksen W. Ecology of Haemophilus, Pasteurella, and Actinobacillus . In: Kilian M, Frederiksen W, Biberstein EL, ed. New York: Academic Press, 1981: 11-38.
17. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989: 33: 1413-1418.
18. Loesche WJ, Schmidt E, Smith BA, Morrison EC, Caffesse R, Hujoel PP. Effects of metronidazole on periodontal treatment needs. J Periodontol 1991: 62: 247-257.
19. Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994: 48: 297-326.
20. Mandell RL, Tripoli LS, Savitt E, Goodson M, Socransky SS. The effect of treatment on Actinobacillus actinomycetemcomitans m localized juvenile periodontitis. J Periodontol 1986: 57: 94-99.
21. Miyake Y, Tsuruda K, Okuda K, Iwamoto Y, Suginaka H. In vitro activity of tetracyclines, macrolides, quinolones, clindamycin, and metronidazole against periodontopathic bacteria. J Periodont Res 1995: 30: 290-293.
22. Modai J. The clincal use of macrolides. J Antimicrob Chemother 1988: 22: 145-153.
23. Moore WEC, Moore LHV. The bacteria of periodontal diseases. Periodontol 2000 1994: 5: 66-77.
24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1993.
25. Nilsen OG. Plasma pharmacokinetics of macrolides with reference to total and free concentrations. 2nd Int. Conference on the Macrolides, Azalides and Streptogramins; January 19-22; Venice, Italy, 1994.
26. Page RC, Schroeder HE. Periodontitis in man and other animals. A comparative review. Basel: Karger, 1982: 45-47.
27. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992: 36: 1241-1243
28. Paolantonio M, Di Girolamo G, Pedrazzoli V et al. Occurrence of Actinobacillus actinomycetemcomitans in patients wearing orthodontic appliances. A cross-sectional study. J Clin Periodontol 1996: 23: 112-118.
29. Pappas JD, Walker C. Gingival crevicular fluid levels of erythromycin and the in vitro effect on periodontal bacteria J Dent Res 1987: 66: 154-159.
30. Pavicic MJAMP, van Winkelhoff AJ, de Graaff J. In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations Antimicrob Agents Chemother 1992: 36: 2634-2638
31. Saarela M, Asikainen S, Alaluusua S, Phyala L, Lai CH, Jousimies-Somer H. Frequency and stability of mono- and poly-infection by Actinobacillus actinomycetemcomitans serotypes a, b, c, d and e. Oral Microbiol Immunol 1992: 7: 277-279.
32. Saxén L, Asikainen S, Kanervo A, Kari K, Jousimies-Somer H. The long-term efficacy of systemic doxycycline medication in the treatment of localized juvenile periodontitis. Arch Oral Biol 1990: 35: 227S-229S.
33. Schack SH, Smith PW, Penn RG, Rapoport JM. Endocarditis caused by Actinobacillus actinomycetemcomitans. J Clin Microbiol 1984: 20: 579-581.
34. Slots J. Salient biochemical characters of Actinobacillus actinomycetemcomitans. Arch Microbiol 1982: 131: 60-67.
35. Slots J. Selective medium for isolation of Actinobacillus actinomycetemcomitans. J Clin Microbiol 1982: 15: 606-609.
36. Slots J. Rapid identification of important periodontal microorganisms by cultivation. Oral Microbiol Immunol 1986: 1: 48-55.
37. Slots J, Evans RT, Lobbins PM, Genco RJ. In vitro antimicrobial susceptibility of Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1980: 18: 9-12.
38. Slots J, Genco RJ. Black-pigmented Bacteroides species, Capnocytophaga species, and Actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival, and tissue destruction. J Dent Res 1984: 63: 412-421.
39. Slots JR, Rams TE. Antibiotics in periodontal therapy: advantages and disadvantages. J Clin Periodontol 1990: 17: 479-493
40. Slots J, Rosling BG, Genco RJ. Suppression of penicillin-resistant oral Actinobacillus actinomycetemcomitans with tetracycline. Considerations in endocarditis prophylaxis. J Periodontol 1983: 54: 193-196.
41. Syed SA, Loesche WJ. Survival of human dental plaque flora in various transport media. Appl Microbiol 1972: 24: 638-644.
42. Tanner ACR, Goodson JM. Sampling of microorganisms associated with periodontal disease. Oral Microbiol Immunol 1986: 1: 15-20.
43. Walker CB, Tyler KT, Low SB, King CJ. Penicillin-degrading enzymes associted with adult periodontitis. Oral Microbiol Immunol 1987: 2: 129-131.
44. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989: 37: 8-41.
45. Zambon JJ, Slots J, Genco RJ. Serology of Actinobacillus actinomycetemcomitans and serotype distribution in human periodonthal disease. Infect Immun 1983 41: 19-27.
46. Zambon JJ. Actinobacillus actinomycetemcomitans in human periodontal disease. J Clin Periodontol 1985: 12: 1-20.
47. Zambon JJ, Umemoto T, De Nardin E, Nakazawa EZ, Christensson LA, Genco RJ. Actinobacillus actinomycetemcomitans in the pathogenesis of human periodontal disease. Adv Dent Res 1988: 2: 269-274.
48. Zambon JJ, Reynolds HS, Genco RJ. Studies of the subgingival microflora in patients with acquired immunodeficiency syndrome. J Periodontol 1990: 61: 699-705.